Tenax Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-52.6M | $-17.6M | $-7.7M | $11.0M | $-32.5M | $-9.9M | $-8.4M | $-14.1M |
| Depreciation & Amortization | — | $0 | $8.0K | $5.1K | $4.1K | $4.1K | $5.0K | $9.0K |
| Depreciation | — | — | $7.6K | $5.1K | $4.1K | $4.1K | $5.0K | $9.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $19.2M | $1.1M | $191.0K | — | — | — | $0 | $190.1K |
| Net Cash from Operating Activities | $-35.8M | $-14.8M | $-5.9M | $-11.4M | $-10.9M | $-9.3M | $-7.6M | $-5.5M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | $2.3K | $5.3K | $3.5K | $3.6K | $7.6K |
| Business Acquisitions | — | — | — | $21.6M | $21.7M | — | — | — |
| Net Cash from Investing Activities | — | $0 | $3.0K | $-2.3K | $452.6K | $20.1K | $-1.7K | $7.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $38.5M | $99.9M | $13.6M | $7.9M | $9.7M | $10.6M | $96.5K | $8.9M |
| Net Change in Cash | — | — | — | — | — | $1.3M | $-7.5M | $10.8M |
| Free Cash Flow | — | — | — | $-11.4M | $-10.9M | $-9.3M | $-7.6M | $-5.5M |